By Josh Beckerman

4D Molecular Therapeutics Inc., a developer of gene-therapy products, has filed for an initial public offering.

Viking Global Investors, which led a $90 million Series B financing round last year, owns a 16% stake. Pfizer Inc. (PFE) owns 11.8%.

4D Molecular, based in Emeryville, Calif., has applied to list on the Nasdaq Global Market under symbol DDDD. The filing lists a placeholder figure of $100 million.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

September 30, 2019 19:40 ET (23:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Pfizer.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Pfizer.